One casualty of the mass firings across federal health agencies are regulators who ensure drugs for pets and livestock are safe and effective.
The cuts hit the Center for Veterinary Medicine, an arm of the Food and Drug Administration that regulates the safety and efficacy of drugs, food and medical devices for animals.
The U.S. Food and Drug Administration has approved Elanco Animal Health's (ELAN.N) skin disease treatment for dogs, the health regulator's website showed on Thursday, sending the company's shares up 2% in afternoon trade.
Roughly 6 million dogs are diagnosed with cancer every year in the U.S. Yet, there aren’t many treatment options. Most chemotherapies in veterinary medicine are human drugs that have been repurposed for dogs and cats with mixed results.
“They’re toxic and they’re expensive,” said Adriann Sax, CEO, president and co-founder of the clinical stage animal health biopharma Vetigenics. “Some pet parents would be willing to … invest $10,000 in chemo.
While humans continue to grapple with shortages of weight loss drugs like Ozempic and Wegovy, their furry friends may soon be in luck: Drug manufacturers are now working to develop comparable GLP-1 drugs for pets.
Elanco president/CEO Jeff Simmons says the animal health firm will ramp up advertising as it enters a “historic” launch phase, plus our policy and Trends segments.
Bausch + Lomb announced on Monday the debut of its Project Watson line of eye, ear and overall wellness products for dogs. The Project Watson product line is set to include eye and ear washes, eyelid and ear wipes, a supplement for tear stain support and a daily chewable for overall health.
Elanco Animal Health Inc has reported Q4 EPS of $0.21 higher than $0.12 reported a year ago, surpassing analysts' view of $0.17.
Revenue was $1.11 billion, a decrease of 2% YY, unfavorably impacted by approximately $60 million of previously disclosed items that benefited Q4 FY20., beating the consensus of $1.10 billion.
Elanco Animal Health (NYSE:ELAN) just announced another acquisition after its deal to acquire Bayer Animal Health last year. This time, the animal health company is purchasing Kindred Biosciences (NASDAQ:KIN) for $440 million. Kindred focuses on dermatology treatments for dogs and cats. Elanco doesn't have a dermatology portfolio today, and management hopes this acquisition can catapult it into a growing new area of pet healthcare.
Shares of Kindred Biosciences (NASDAQ:KIN) soared 46% on Wednesday after the pet-focused biotech company said it agreed to be acquired by Elanco Animal Health (NYSE:ELAN).